Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis MSI-H metastatic CRC is rare and its impact on outcomes is unknown We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC)
Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis MSI-H metastatic CRC is rare and its impact on outcomes is unknown We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC)
Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis MSI-H metastatic CRC is rare and its impact on outcomes is unknown We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation
Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis MSI-H metastatic CRC is rare and its impact on outcomes is unknown We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC) A retrospective
Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) original articles 7 Crane CH, Iacobuzio-Donahue CA Keys to personalized care in pancreatic oncology J Clin Oncol 2012; 30: 4049–4050 8 Mahadevan D, Von Hoff DD Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol Cancer Ther 2007; 6: 1186–1197 9
Multicenter retrospective analysis of metastatic colorectal cancer (CRC . . . The poorer survival of metastatic MSI CRC seems in part to be driven by the BRAF mutation (Goldstein et al, 2014) MSI CRC also appears to have a lower recurrence rate than MSS …” Section: Metastatic and Recurrent Colorectal Cancer With Msimentioning confidence: 97% See 1 more Smart Citation
Microsatellite Instability and Metastatic Colorectal Cancer – A . . . Abstract Approximately 4-5% of patients with metastatic colorectal cancer (mCRC) have mismatch repair deficient (dMMR) microsatellite instability-high (MSI-H) tumours These tumours present challenges in the clinical practice due to variant response to fluoropyrimidine-based chemotherapy and, perhaps, also non-immunologic targeted therapies